Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers

被引:52
作者
Bowers, WJ
Howard, DF
Brooks, AI
Halterman, MW
Federoff, HJ
机构
[1] Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Div Mol Med & Gene Therapy, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA
关键词
HSV; amplicon; gene therapy; titer; GFP; beta-galactosidase;
D O I
10.1038/sj.gt.3301340
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently developed helper virus-free methods of herpes simplex virus (HSV) amplicon vector packaging provide stocks that are virtually devoid of the cytotoxic component normally associated with traditional helper virus-based packaging methods. These approaches involve cotransfection of amplicon plasmid DNA with either a five-cosmid set or a bacterial artificial chromosome (BAC) that contains the HSV genome without its cognate pac signals. Helper virus-free amplicon packaging produces low-titer stocks (<10(5) expressing particles/ml) that exhibit a high frequency of pseudotransduction. In an effort to enhance amplicon titers, we introduced in trans a genomic copy of the virion host shutoff (vhs) protein-encoding gene UL41 into both cosmid- and BAG-based packaging strategies. Cotransfection of this plasmid with the amplicon and packaging reagents results in a 10-fold higher amplicon titer, and stocks that do not exhibit the pseudotransduction phenomenon. To further enhance packaging efficiency, the HSV transcriptional activator VP16 was introduced into packaging cells 1 day before the packaging components. Pre-loading of packaging cells with VP16 led to an additional enhancement of amplicon titers, an effect that did not occur in the absence of vhs. Increased helper virus-free amplicon titers resulting from these modifications will make in vivo transduction experiments more feasible.
引用
收藏
页码:111 / 120
页数:10
相关论文
共 33 条
[1]   Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results [J].
Alexander, IE ;
Russell, DW ;
Miller, AD .
HUMAN GENE THERAPY, 1997, 8 (16) :1911-1920
[2]   A COSMID-BASED SYSTEM FOR CONSTRUCTING MUTANTS OF HERPES-SIMPLEX VIRUS TYPE-1 [J].
CUNNINGHAM, C ;
DAVISON, AJ .
VIROLOGY, 1993, 197 (01) :116-124
[3]   EXPRESSION OF NERVE GROWTH-FACTOR INVIVO FROM A DEFECTIVE HERPES-SIMPLEX VIRUS-1 VECTOR PREVENTS EFFECTS OF AXOTOMY ON SYMPATHETIC-GANGLIA [J].
FEDEROFF, HJ ;
GESCHWIND, MD ;
GELLER, AI ;
KESSLER, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1636-1640
[4]  
Federoff Howard J., 1995, P109, DOI 10.1016/B978-012397570-6/50009-5
[5]   Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells [J].
Fraefel, C ;
Song, S ;
Lim, F ;
Lang, P ;
Yu, L ;
Wang, YM ;
Wild, P ;
Geller, AI .
JOURNAL OF VIROLOGY, 1996, 70 (10) :7190-7197
[6]  
FRENKEL N, 1982, EUKARYOTIC VIRAL VEC, P205
[7]   AN EFFICIENT DELETION MUTANT PACKAGING SYSTEM FOR DEFECTIVE HERPES-SIMPLEX VIRUS VECTORS - POTENTIAL APPLICATIONS TO HUMAN GENE-THERAPY AND NEURONAL PHYSIOLOGY [J].
GELLER, AI ;
KEYOMARSI, K ;
BRYAN, J ;
PARDEE, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8950-8954
[8]   A DEFECTIVE HSV-1 VECTOR EXPRESSES ESCHERICHIA-COLI BETA-GALACTOSIDASE IN CULTURED PERIPHERAL NEURONS [J].
GELLER, AI ;
BREAKEFIELD, XO .
SCIENCE, 1988, 241 (4873) :1667-1669
[9]  
GESCHWIND M, 1994, PROVIDING PHARM ACCE, P462
[10]   Differential effects of nerve growth factor and dexamethasone on herpes simplex virus type 1 oriL- and oriS-dependent DNA replication in PC12 cells [J].
Hardwicke, MA ;
Schaffer, PA .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3580-3587